Recursion Pharmaceuticals AI Price Prediction

The company is currently unprofitable, as reflected in its negative EPS and PE ratio. This indicates ongoing operating losses and a business model that has yet to demonstrate earnings leverage. From a pure financial-performance standpoint, the risk profile remains elevated until there is clear visibility into a path to profitability.

• Negative EPS of -1.84 signals that the company is losing money on a per-share basis, consistent with an early-stage or R&D-heavy biotech profile.
• A PE ratio of -1.88 underscores the lack of positive earnings and means traditional valuation metrics based on earnings are not supportive at this stage.
• Given the lack of profitability, investors are relying on future growth and pipeline execution rather than current financial strength, which raises downside risk if expectations are not met.

The stock has declined sharply, down 24.9% over the last month, and is trading well below its 200-day moving average, indicating a strong downtrend. An RSI of 27.19 suggests the stock is in oversold territory, which can sometimes precede a short-term bounce but also reflects intense recent selling pressure. Overall, the technical setup is weak, with any near-term upside more likely to be a tactical rebound than a confirmed trend reversal.

• Current price of $3.46 is significantly below the 200-day moving average of $4.92, confirming a sustained bearish trend and negative longer-term momentum.
• A 24.9% decline in the last month indicates strong negative sentiment and potential capitulation, often associated with risk-off behavior among investors.
• RSI at 27.19 is in oversold territory, which may signal the potential for a short-term technical bounce but does not, by itself, negate the broader downtrend.

Overall, the setup for Recursion Pharmaceuticals leans bearish at this time. The stock is in a pronounced downtrend, trading well below its long-term moving average, and the company remains unprofitable with negative earnings. While alternative data show encouraging growth in digital engagement and brand awareness, these positives are not yet strong enough to outweigh the current financial and technical weaknesses.

• Persistent losses and a negative PE ratio, combined with a sharp recent price decline and sub-200-day trading level, point to elevated risk and a bearish near- to medium-term outlook.
• Growing online and social media presence offers some longer-term narrative support, but until there is clearer progress toward profitability or a technical trend reversal, the stock’s risk/reward profile remains skewed to the downside.